Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 4.1%, or $19.25, after results are released.
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $433.00. The company’s shares ...
Bruker Corporation announced the launch of the VERTEX NEO Platform with its first product, the VERTEX NEO R. This release marks a continuation of providing high-end Fourier-Transform Infrared (FTIR) ...
Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...
The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...
The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan â„¢ interferometer, which provides PEAK spectral resolution. The precise linear ...
VVX insiders have traded $VVX stock on the open market 14 times in the past 6 months. Of those trades, 7 have been purchases and 7 have been sales. Here’s a ...
UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...
Vertex AI and high performance computing make it faster and easier to detect space storms SUNNYVALE, Calif., Jan. 28, 2025 /PRNewswire/ -- The Aerospace Corporation (Aerospace), a national ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...